Please note that the details of this Challenge are no longer open. This challenge is closed and is no longer accepting new submissions. You can:
Challenge AstraZeneca Challenge: Digital Health Solutions for Clinical Trial Acceleration or Improved Clinical Outcomes

AstraZeneca Challenge: Digital Health Solutions for Clinical Trial Acceleration or Improved Clinical Outcomes

Award: varies
Deadline: Closed
Active Solvers: 246
Posted: May 22 2017
Challenge ID: 9933831
Share Challenge Share

With the growth in digital technologies, patients are becoming increasingly able to monitor and impact their own health via apps, wearable sensors and digital therapeutics. With access to data at their fingertips, patients are empowered to take an active role in managing their care. As a result, they also expect medical care to become more personalised and effective. This provides many opportunities for the pharmaceutical industry to explore and embrace new technologies and enhance the way we approach patient care. AstraZeneca is seeking collaboration partners who can help us improve clinical outcomes and disease management for the benefit of both patients and healthcare professionals. 

This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.


Digital health is rapidly shaping the way in which healthcare is delivered to patients. The pharmaceutical industry is poised to take advantage of many opportunities, including big data, wearable technologies, improved clinical trial enrollment and more. AstraZeneca is looking to collaborate in these areas, as well as in new areas yet to be defined. Ideally, the collaboration would be at the academic stage with some early results available to show its potential. Successful proposals should focus on technologies and approaches that will benefit patients and integrate with the AstraZeneca main therapy areas:  Oncology, Cardiovascular & Metabolic Diseases and Respiratory. 

This is an electronic Request-for-Partners (eRFP) Challenge. The Solver will write a preliminary proposal (maximum of 10 pages, including supporting non-confidential information and contact details) to be evaluated by AstraZeneca with a goal of establishing a collaborative partnership. Upon completion of the evaluation, AstraZeneca may contact selected Solvers directly to work out terms for a collaboration contract. The monetary value of the contract will vary depending on the amount of work to be delivered and the agreed time frame. 

[NOTE: Only proposals from Solvers who have the ability to work as a collaboration partner will be considered.] 

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on July 24, 2017. 

Late submissions will not be considered


AstraZeneca is a global, science-led, biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular & Metabolic Diseases and Respiratory.  AstraZeneca also is selectively active in the areas of autoimmunity, neuroscience and infection. As an innovation-driven research organisation, AstraZeneca recognises that great ideas come from many sources. Open innovation is an avenue by which ideas can be shared and AstraZeneca recently launched a pavilion to further its commitment to facilitate the advancement of pharmaceutical research.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is an eRFP Challenge?

eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.

After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.

This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.

Share This Challenge